In the rapidly evolving landscape of biotherapeutics, the success of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) hinges on more than just antigen recognition. While the Fab region dictates specificity, the Fc region (Fragment crystallisable) governs the molecule’s clinical fate—influencing everything from half-life to immune-mediated effector functions.
The strategic necessity of FcR characterisation
In antibody drug discovery, characterising the interaction between an antibody and Fc receptors (FcRs) is not just a regulatory requirement; it is a strategic necessity for optimising therapeutic efficacy and safety. A primary challenge for researchers is ensuring that recombinant Fc receptors behave in a “native-like” manner and exhibit true functional authenticity.
To address this, Sino Biological has validated the binding affinities of its Fc receptors across various IgG subclasses using Surface Plasmon Resonance (SPR)—the industry’s “gold standard” for kinetic analysis. Results demonstrate that Sino Biological’s Fc receptors exhibit binding profiles highly consistent with established literature. This alignment confirms the proteins’ authentic conformational integrity, positioning them as essential tools for reliable antibody evaluation.
Biological significance and standard affinity of FcR binding
In antibody drug discovery, characterizing the interaction between an antibody and Fc receptors (FcRs) is not just a regulatory requirement; it is a strategic necessity for optimizing therapeutic efficacy and safety. A primary challenge for researchers is ensuring that recombinant Fc receptors behave in a “native-like” manner and exhibit true functional authenticity.
To address this, Sino Biological has rigorously validated the binding affinities of its Fc receptors across various IgG subclasses using Surface Plasmon Resonance (SPR)—the industry’s “gold standard” for kinetic analysis. Results demonstrate that Sino Biological’s Fc receptors exhibit binding profiles highly consistent with established literature. This alignment confirms the proteins’ authentic conformational integrity, positioning them as essential tools for reliable antibody evaluation.
Biological significance and standard affinity of FcR binding
Fc receptors serve as the essential bridge between the adaptive and innate immune systems. When an antibody binds to its target, the Fc region connects target recognition to downstream immune responses through interactions with Fc receptors expressed on innate immune cells. These interactions trigger critical mechanisms, including:
- Antibody-dependent cellular cytotoxicity (ADCC): Mediated by FcγRIIIa.
- Antibody-dependent cellular phagocytosis (ADCP): Mediated by FcγRIIa.
- Serum half-life regulation: Via the neonatal Fc receptor (FcRn).
However, not all Fc receptors share the same function or affinity for IgG subclasses. The human immune system expresses a diverse array of FcRs, including FcγRI (CD64), FcγRII (CD32a/b), and FcγRIII (CD16a/b), each with distinct affinities. Furthermore, genetic polymorphisms—such as the V158/F158 variants of CD16a—can dramatically alter binding kinetics, leading to variations in patient response during clinical trials.
As a leading manufacturer of recombinant proteins and antibodies, Sino Biological provides a comprehensive collections of human Fc receptors that are “must-have” in antibody binding tests and validations. Sino has conducted extensive validation of its FcR series—including FcγRI (CD64), FcγRII (CD32a/b), and FcγRIII (CD16a/b)—against human IgG1 and IgG4 subclasses. Data demonstrates a binding profile that is highly consistent with the values reported, confirming the “native-like” conformation and bioactivity of Sino’s proteins.
Why choose Sino Biological’s Fc receptors?
- High fidelity & bioactivity: Sino Biological’s Fc receptors are expressed in mammalian systems to ensure proper folding and glycosylation, closely mimicking the true behavior of FcRs in the human body.
- Polymorphic accuracy: Sino offers the full range of polymorphic variants (e.g., CD16a 158V/F, CD32a 131H/R), allowing screen for patient-specific variability early in development.
- Lot-to-lot consistency: Sino’s QC on purity by HPLC/MALS and activity by SPR/BLI ensures the consistency of every batch of the products.
- Optimised for SPR: Sino’s Fc receptors are available with His-tag version as well as His-Avi Biotinylating version to facilitate different ways of screening using SPR assay.
In the competitive race to bring new antibodies and ADCs to market, the accuracy of the analytical data is the most important thing along the way of drug development. By providing Fc receptors that are validated to match the reported binding affinities, Sino Biological offers the clients the functional authenticity required for reliable antibody profiling.
